{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T03:50:06Z","timestamp":1784951406215,"version":"3.55.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ad.2024.07.007","type":"journal-article","created":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T00:34:32Z","timestamp":1720226072000},"page":"T781-T790","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["[Translated article] Risk of Skin Cancer Associated with Disease-Modifying Therapies in Multiple Sclerosis: A Comprehensive Evidence Review"],"prefix":"10.1016","volume":"115","author":[{"given":"M.","family":"Brufau-Cochs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mansilla-Polo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Morgado-Carrasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2024.07.007_bib0335","first-page":"1","article-title":"Multiple sclerosis","volume":"4","author":"Filippi","year":"2018","journal-title":"Nat Rev Dis Primer."},{"key":"10.1016\/j.ad.2024.07.007_bib0340","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple Sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ad.2024.07.007_bib0345","doi-asserted-by":"crossref","first-page":"824926","DOI":"10.3389\/fneur.2022.824926","article-title":"Therapeutic Advances in Multiple Sclerosis","volume":"13","author":"Yang","year":"2022","journal-title":"Front Neurol."},{"key":"10.1016\/j.ad.2024.07.007_bib0350","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.nrl.2016.02.026","article-title":"Consenso para el tratamiento de la esclerosis m\u00faltiple 2016. Sociedad Espa\u00f1ola de Neurolog\u00eda","volume":"32","author":"Garc\u00eda Merino","year":"2017","journal-title":"Neurolog\u00eda."},{"key":"10.1016\/j.ad.2024.07.007_bib0355","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/ene.13536","article-title":"ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis","volume":"25","author":"Montalban","year":"2018","journal-title":"Eur J Neurol."},{"key":"10.1016\/j.ad.2024.07.007_bib0360","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1212\/WNL.0000000000005345","article-title":"Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology."},{"key":"10.1016\/j.ad.2024.07.007_bib0365","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.japh.2022.07.009","article-title":"Comparative efficacy and safety of disease-modifying therapies in patients with relapsing multiple sclerosis: A systematic review and network meta-analysis","volume":"63","author":"Chen","year":"2023","journal-title":"J Am Pharm Assoc."},{"key":"10.1016\/j.ad.2024.07.007_bib0370","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11940-021-00677-1","article-title":"Early Aggressive Treatment Approaches for Multiple Sclerosis","volume":"23","author":"Simpson","year":"2021","journal-title":"Curr Treat Options Neurol."},{"key":"10.1016\/j.ad.2024.07.007_bib0375","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s40263-018-0564-y","article-title":"Cancer Risk in Patients with Multiple Sclerosis: Potential Impact of Disease-Modifying Drugs","volume":"32","author":"Lebrun","year":"2018","journal-title":"CNS Drugs."},{"key":"10.1016\/j.ad.2024.07.007_bib0380","doi-asserted-by":"crossref","first-page":"103681","DOI":"10.1016\/j.msard.2022.103681","article-title":"S1P receptor modulators in Multiple Sclerosis: Detecting a potential skin cancer safety signal","volume":"59","author":"Vasileios-Periklis","year":"2022","journal-title":"Mult Scler Relat Disord."},{"key":"10.1016\/j.ad.2024.07.007_bib0385","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMct1101691","article-title":"Fingolimod for Multiple Sclerosis","volume":"366","author":"Pelletier","year":"2012","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ad.2024.07.007_bib0390","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.3390\/ijms21082950","article-title":"Multiple Sclerosis Treatment and Melanoma Development","volume":"21","author":"Carbone","year":"2020","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.ad.2024.07.007_bib0395","unstructured":"EMA, Gilenya, European Medicines Agency, 2018. [consultado 30 Jul 2023]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/gilenya"},{"key":"10.1016\/j.ad.2024.07.007_bib0400","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.jid.2019.02.010","article-title":"Human Keratinocytes Use Sphingosine 1-Phosphate and its Receptors to Communicate\u00a0Staphylococcus aureus Invasion\u00a0and Activate Host Defense","volume":"139","author":"Igawa","year":"2019","journal-title":"J Invest Dermatol."},{"key":"10.1016\/j.ad.2024.07.007_bib0405","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/ced.12037","article-title":"Sphingosine 1-phosphate attenuates peroxide-induced apoptosis in HaCaT cells cultured in vitro","volume":"38","author":"Moriue","year":"2013","journal-title":"Clin Exp Dermatol."},{"key":"10.1016\/j.ad.2024.07.007_bib0410","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3390\/biology11060809","article-title":"Sphingosine 1-Phosphate Signaling at the Skin Barrier Interface","volume":"11","author":"Masuda-Kuroki","year":"2022","journal-title":"Biology."},{"key":"10.1016\/j.ad.2024.07.007_bib0415","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1111\/jphp.12588","article-title":"Fingolimod hydrochloride gel shows promising therapeutic effects in a mouse model of atopic dermatitis","volume":"68","author":"Tamakuwala","year":"2016","journal-title":"J Pharm Pharmacol."},{"key":"10.1016\/j.ad.2024.07.007_bib0420","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/S0140-6736(14)60803-5","article-title":"Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"384","author":"Vaclavkova","year":"2014","journal-title":"Lancet Lond Engl."},{"key":"10.1016\/j.ad.2024.07.007_bib0425","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1212\/WNL.0000000000004293","article-title":"Five cases of malignant melanoma during fingolimod treatment in Dutch patients with MS","volume":"89","author":"Killestein","year":"2017","journal-title":"Neurology."},{"key":"10.1016\/j.ad.2024.07.007_bib0430","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1212\/WNL.0000000000001462","article-title":"Long-term effects of fingolimod in multiple sclerosis","volume":"84","author":"Kappos","year":"2015","journal-title":"Neurology."},{"key":"10.1016\/j.ad.2024.07.007_bib0435","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ad.2024.07.007_bib0440","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1136\/jnnp-2015-310597","article-title":"Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study","volume":"87","author":"Cohen","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"10.1016\/j.ad.2024.07.007_bib0445","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(15)01314-8","article-title":"Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Lublin","year":"2016","journal-title":"Lancet Lond Engl."},{"key":"10.1016\/j.ad.2024.07.007_bib0450","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419878324","article-title":"Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results","volume":"12","author":"Cohen","year":"2019","journal-title":"Ther Adv Neurol Disord."},{"key":"10.1016\/j.ad.2024.07.007_bib0455","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet Lond Engl."},{"key":"10.1016\/j.ad.2024.07.007_bib0460","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S1474-4422(19)30238-8","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial","volume":"18","author":"Cohen","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ad.2024.07.007_bib0465","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1474-4422(19)30239-X","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial","volume":"18","author":"Comi","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ad.2024.07.007_bib0470","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/jamaneurol.2021.0405","article-title":"Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial","volume":"78","author":"Kappos","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ad.2024.07.007_bib0475","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1177\/13524585211003291","article-title":"Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry","volume":"27","author":"Theodorsdottir","year":"2021","journal-title":"Mult Scler J."},{"key":"10.1016\/j.ad.2024.07.007_bib0480","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1212\/NXI.0000000000000158","article-title":"No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine","volume":"2","author":"Pakpoor","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"10.1016\/j.ad.2024.07.007_bib0485","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.ad.2019.01.011","article-title":"Clinical Management of Cutaneous Adverse Events in Patients on Chemotherapy: A National Consensus Statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology","volume":"110","author":"Sanmart\u00edn","year":"2019","journal-title":"Actas Dermosifiliogr."},{"key":"10.1016\/j.ad.2024.07.007_bib0490","doi-asserted-by":"crossref","first-page":"e990","DOI":"10.1212\/NXI.0000000000000990","article-title":"Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment","volume":"8","author":"Rolfes","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"10.1016\/j.ad.2024.07.007_bib0495","article-title":"Alopecia in Multiple Sclerosis Patients Treated with Disease Modifying Therapies","volume":"14","author":"Porwal","year":"2022","journal-title":"J Cent Nerv Syst Dis."},{"key":"10.1016\/j.ad.2024.07.007_bib0500","doi-asserted-by":"crossref","first-page":"e0188120","DOI":"10.1371\/journal.pone.0188120","article-title":"Decreased prevalence of cancer in patients with multiple sclerosis: A case-control study","volume":"12","author":"Moisset","year":"2017","journal-title":"PLoS One."},{"key":"10.1016\/j.ad.2024.07.007_bib0505","doi-asserted-by":"crossref","first-page":"12533","DOI":"10.1038\/s41598-021-91912-x","article-title":"Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients","volume":"11","author":"Gil-Bernal","year":"2021","journal-title":"Sci Rep."},{"key":"10.1016\/j.ad.2024.07.007_bib0510","doi-asserted-by":"crossref","first-page":"621856","DOI":"10.3389\/fphar.2021.621856","article-title":"Different Doses of Fingolimod in Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"12","author":"Wu","year":"2021","journal-title":"Front Pharmacol."},{"key":"10.1016\/j.ad.2024.07.007_bib0515","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1007\/s00415-021-10931-w","article-title":"Long-term real-world effectiveness and safety of fingolimod over 5\u00a0years in Germany","volume":"269","author":"Ziemssen","year":"2022","journal-title":"J Neurol."},{"key":"10.1016\/j.ad.2024.07.007_bib0520","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.2147\/NDT.S147874","article-title":"New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab","volume":"14","author":"Frau","year":"2018","journal-title":"Neuropsychiatr Dis Treat."},{"key":"10.1016\/j.ad.2024.07.007_bib0525","series-title":"Informe de Posicionamiento Terap\u00e9utico de ocrelizumab (Ocrevus \u00ae) en esclerosis m\u00faltiple","author":"Sancho-L\u00f3pez","year":"2019"},{"key":"10.1016\/j.ad.2024.07.007_bib0530","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1080\/14740338.2023.2224556","article-title":"A safety review of current monoclonal antibodies used to treat multiple sclerosis","volume":"22","author":"Costa","year":"2023","journal-title":"Expert Opin Drug Saf."},{"key":"10.1016\/j.ad.2024.07.007_bib0535","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s13311-021-01073-y","article-title":"Association Between Disease-Modifying Therapies Prescribed to Persons with Multiple Sclerosis and Cancer: a WHO Pharmacovigilance Database Analysis","volume":"18","author":"Dolladille","year":"2021","journal-title":"Neurotherapeutics."},{"key":"10.1016\/j.ad.2024.07.007_bib0540","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1007\/s00415-020-09983-1","article-title":"Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223","volume":"267","author":"Steingo","year":"2020","journal-title":"J Neurol."},{"key":"10.1016\/j.ad.2024.07.007_bib0545","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2147\/TCRM.S134398","article-title":"Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis","volume":"13","author":"Guarnera","year":"2017","journal-title":"Ther Clin Risk Manag."},{"key":"10.1016\/j.ad.2024.07.007_bib0550","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1007\/s40265-020-01422-9","article-title":"The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review","volume":"80","author":"Rammohan","year":"2020","journal-title":"Drugs."},{"key":"10.1016\/j.ad.2024.07.007_bib0555","doi-asserted-by":"crossref","first-page":"102572","DOI":"10.1016\/j.msard.2020.102572","article-title":"Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis","volume":"46","author":"Leist","year":"2020","journal-title":"Mult Scler Relat Disord."},{"key":"10.1016\/j.ad.2024.07.007_bib0560","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s40120-020-00204-5","article-title":"Effects on Melanoma Cell Lines Suggest No Significant Risk of Melanoma Under Cladribine Treatment","volume":"9","author":"Lebrun-Frenay","year":"2020","journal-title":"Neurol Ther."},{"key":"10.1016\/j.ad.2024.07.007_bib0565","first-page":"788","article-title":"Incidence trends of nonmelanoma skin cancer in Germany from 1998 to 2010","volume":"13","author":"Rudolph","year":"2015","journal-title":"J Dtsch Dermatol Ges."},{"key":"10.1016\/j.ad.2024.07.007_bib0570","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ad.2015.12.008","article-title":"Skin Cancer Incidence and Mortality in Spain: A Systematic Review and Meta-Analysis","volume":"107","author":"Tejera-Vaquerizo","year":"2016","journal-title":"Actas Dermosifiliogr."},{"key":"10.1016\/j.ad.2024.07.007_bib0575","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/j.1365-2133.2009.09468.x","article-title":"Population-based incidence of basal cell carcinoma in a Spanish Mediterranean area","volume":"161","author":"Bielsa","year":"2009","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2024.07.007_bib0580","doi-asserted-by":"crossref","first-page":"E264","DOI":"10.1111\/ctr.12094","article-title":"Cancer risk with alemtuzumab following kidney transplantation","volume":"27","author":"Puttarajappa","year":"2013","journal-title":"Clin Transplant."},{"key":"10.1016\/j.ad.2024.07.007_bib0585","unstructured":"EMA, New recommendations to minimise risks of the rare brain infection PML and a type skin cancer with Gilenya, European Medicine Agency, 2018. [Consultado 30 Jul 2023]. Available from: https:\/\/www.ema.europa.eu\/en\/news\/new-recommendations-minimise-risks-rare-brain-infection-pml-and-type-skin-cancer-gilenya"},{"key":"10.1016\/j.ad.2024.07.007_bib0590","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40268-022-00407-1","article-title":"Analyses of Basal and Squamous Cell Carcinoma Reported as an Adverse Drug Reaction and Comparison with Cases from the Cancer Registry from Germany","volume":"23","author":"Dubrall","year":"2023","journal-title":"Drugs RD."},{"key":"10.1016\/j.ad.2024.07.007_bib0595","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/bjd.19880","article-title":"Risk of skin cancer in new users of thiazides and thiazide-like diuretics: a cohort study using an active comparator group","volume":"185","author":"Schneider","year":"2021","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2024.07.007_bib0600","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.jaad.2017.11.042","article-title":"Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A\u00a0nationwide case-control study from Denmark","volume":"78","author":"Pedersen","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2024.07.007_bib0605","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jaad.2023.04.035","article-title":"Hydrochlorothiazide use and risk of keratinocyte carcinoma and melanoma: A multisite population-based cohort study","volume":"89","author":"Azoulay","year":"2023","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2024.07.007_bib0610","doi-asserted-by":"crossref","first-page":"T784","DOI":"10.1016\/j.ad.2023.08.002","article-title":"Long-Term Safety Profile and Off-Label Use of JAK Inhibitors in Dermatological Disorders","volume":"114","author":"Corbella-Bagot","year":"2023","journal-title":"Actas Dermosifiliogr."},{"key":"10.1016\/j.ad.2024.07.007_bib0615","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.therap.2022.04.005","article-title":"Skin cancers under Janus kinase inhibitors: A World Health Organization drug safety database analysis","volume":"77","author":"Jalles","year":"2022","journal-title":"Therapie."},{"key":"10.1016\/j.ad.2024.07.007_bib0620","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/sj.bjc.6604796","article-title":"Use of oral glucocorticoids and risk of skin cancer and non-Hodgkin's lymphoma: a population-based case\u2013control study","volume":"100","author":"Jensen","year":"2009","journal-title":"Br J Cancer."},{"key":"10.1016\/j.ad.2024.07.007_bib0625","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3109\/09546634.2011.590792","article-title":"Cyclosporine and skin cancer: an international dermatologic perspective over 25 years of experience. A comprehensive review and pursuit to define safe use of cyclosporine in dermatology","volume":"23","author":"Muellenhoff","year":"2012","journal-title":"J Dermatol Treat."},{"key":"10.1016\/j.ad.2024.07.007_bib0630","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaad.2017.09.063","article-title":"Azathioprine and risk of multiple keratinocyte cancers","volume":"78","author":"Cho","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2024.07.007_bib0635","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/14740338.2018.1400530","article-title":"Skin cancer associated with commonly prescribed drugs: tumor necrosis factor alpha inhibitors (TNF-\u03b1Is), angiotensin-receptor blockers (ARBs), phosphodiesterase type 5 inhibitors (PDE5Is) and statins -weighing the evidence","volume":"17","author":"Nardone","year":"2018","journal-title":"Expert Opin Drug Saf."},{"key":"10.1016\/j.ad.2024.07.007_bib0640","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1002\/ijc.33934","article-title":"Cancer risk and mortality after solid organ transplantation: A population-based 30-year cohort study in Finland","volume":"150","author":"Friman","year":"2022","journal-title":"Int J Cancer."},{"key":"10.1016\/j.ad.2024.07.007_bib0645","doi-asserted-by":"crossref","first-page":"1189680","DOI":"10.3389\/fmed.2023.1189680","article-title":"Skin cancer in solid organ transplant recipients: still an open problem","volume":"10","author":"Granata","year":"2023","journal-title":"Front Med."},{"key":"10.1016\/j.ad.2024.07.007_bib0650","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1111\/ajt.14382","article-title":"Skin Cancers in Organ Transplant Recipients","volume":"17","author":"Mittal","year":"2017","journal-title":"Am J Transplant."},{"key":"10.1016\/j.ad.2024.07.007_bib0655","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/tri.13493","article-title":"Predicting skin cancer in organ transplant recipients: development of the SUNTRAC screening tool using data from a multicenter cohort study","volume":"32","author":"Jambusaria-Pahlajani","year":"2019","journal-title":"Transpl Int."},{"key":"10.1016\/j.ad.2024.07.007_bib0660","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamadermatol.2022.4820","article-title":"External Validation of the Skin and UV Neoplasia Transplant Risk Assessment Calculator (SUNTRAC) in a Large European Solid Organ Transplant Recipient Cohort","volume":"159","author":"G\u00f3mez-Tom\u00e1s","year":"2023","journal-title":"JAMA Dermatol."}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731024005799?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731024005799?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T11:24:42Z","timestamp":1725189882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731024005799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":66,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0001731024005799"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2024.07.007","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated article] Risk of Skin Cancer Associated with Disease-Modifying Therapies in Multiple Sclerosis: A Comprehensive Evidence Review","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2024.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2024.01.022","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}